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E-mail address: choudhuryg@uthscsa.edu (G.G. CheEF2 phosphorylation is under tight control to maintain mRNA translation elongation. We report
that TGFb activates eEF2 by decreasing eEF2 phosphorylation and simultaneously increasing eEF2
kinase phosphorylation. Remarkably, inhibition of Erk1/2 blocked the TGFb-induced dephosphoryl-
ation and phosphorylation of eEF2 and eEF2 kinase. TGFb increased phosphorylation of p90Rsk in an
Erk1/2-dependent manner. Inactive p90Rsk reversed TGFb-inhibited phosphorylation of eEF2 and
suppressed eEF2 kinase activity. Finally, inactive p90Rsk signiﬁcantly attenuated TGFb-induced pro-
tein synthesis and hypertrophy of mesangial cells. These results present the ﬁrst evidence that TGFb
utilizes the two layered kinase module Erk/p90Rsk to activate eEF2 for increased protein synthesis
during cellular hypertrophy.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Transforming growth factor-b (TGFb) is an enforcer of diverse
functions including immune regulation, wound healing, cell prolif-
eration and migration, apoptosis and extracellular matrix expan-
sion [1]. The active TGFb dimer elicits these biological activities
by binding to type II receptor, which phosphorylates the type I
receptor at GS domain, a 30 amino acid segment, located immedi-
ately upstream of the kinase domain [1]. Activated type I receptor
in the tetrameric complex recruits the TGFb receptor-speciﬁc R-
Smads2/3 to phosphorylate at the C-terminal serine residues.
Phosphorylated Smads dissociate from the cytoplasmic retention
protein SARA to expose the nuclear localization signal and translo-
cate to the nucleus and associate with common Smad, Smad4 [2].
The heterodimeric Smad complex then associates with other
DNA binding transcription factors and transcriptional coactivator
or corepressor to induce or repress gene expression [1,2]. However,
Smad-independent TGFb signaling also coexists with the canonical
Smad pathway. These pathways include Erk1/2, JNK and p38 MAPKlf of the Federation of European Bi
edicine, University of Texas
2, 7703 Floyd Curl Drive, San
oudhury).[1]. We and others have recently shown that TGFb activates
phosphatidylinositol 3 kinase/Akt cascade to increase expression
of collagen I and ﬁbronectin, two proﬁbrotic genes [3,4].
TGFb contributes to nephropathy, which consists of whole kid-
ney and glomerular hypertrophy and altered glomerular hemody-
namics [5]. Increased glomerular volume correlates with
hypertrophy of mesangial cells, which constitute a third of the glo-
merular cell population that leads to accumulation of matrix pro-
teins and glomerulosclerosis [6]. We have recently reported
involvement of TGFb-induced PI 3 kinase/Akt signaling in the
development of glomerular, especially mesangial cell hypertrophy,
during the progression of diabetic nephropathy [7].
Cellular hypertrophy is deﬁned by the increase in protein syn-
thesis with minimal changes in DNA synthesis [8]. About 95% of
mRNAs are translated in a cap-dependent manner, where transla-
tion initiation phase acts as the rate-limiting step [9]. We have re-
cently demonstrated a role of TGFb-stimulated TORC1 activity in
inactivation of the translation repressor 4EBP-1, which contributes
to formation of initiation complex 4F by releasing the eIF4E to in-
duce cap-dependent mRNA translation [9,10]. However, it is during
the elongation phase that peptide synthesis occurs in both cap-
dependent and -independent translation. The 93 kD eukaryotic
elongation factor 2 (eEF2), when bound to GTP in its N-terminal
segment, mediates the translocation of aminoacyl tRNA during
elongation [11,12]. Phosphorylation of threinone-56 in this domainochemical Societies.
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eEF2 kinase (eEF2K) that phosphorylates eEF2 at Thr-56 is unusual
in that it is not a member of the Ser–Thr or Tyr kinase superfamily
[13]. The N-terminus of eEF2K contains a calmodulin binding site
and its activity is normally dependent upon Ca2+ and calmodulin
[11]. Several serine residues including Ser-366 have been identiﬁed
in the eEF2K, which are phosphorylated by different stimuli that
speciﬁcally activate kinases such as S6 kinase, Rsk1/2, SAPK4,
CDC2, PKA and MK-2 [11,14,15]. Insulin- and IGF-1-mediated acti-
vation of receptor tyrosine kinases induces phosphorylation of
eEF2K at Ser-366, which impairs its activity towards eEF2, result-
ing in increased elongation of protein synthesis [11,16]. How
eEF2 phosphorylation is regulated by eEF2K in response to ser-
ine–threonine kinase receptor activation is not known.
In the present study, we demonstrate that TGFb induces
dephosphorylation of eEF2 with concomitant increase in phos-
phorylation of eEF2K. These phosphorylation events are sensitive
to activation of Erk1/2 and its target p90 ribosomal S6 kinase
(Rsk). Finally, we demonstrate that TGFb-stimulated p90Rsk con-
tributes to mesangial cell protein synthesis and hypertrophy.
2. Materials and methods
2.1. Materials
Recombinant TGFb was purchased from R & D Systems. Phos-
pho-eEF2 (Thr-56), eEF2, phospho-eEF2K (Ser-366), eEF2K, phos-
pho-Erk1/2 (Thr-202/Tyr-204), Erk1/2, phospho-p90Rsk (Ser-380)
and p90Rsk antibodies were obtained from Cell Signaling Technol-
ogy. Anti-actin antibody was obtained from Sigma. Anti-HA anti-
body was purchased from Covance. Dominant negative Erk2
expression vector has been described previously [17]. Expression
of dominant negative Erk2 blocks the kinase activity of both Erk1
and Erk2 [18]. Dominant negative p90Rsk1 plasmid (pKH3 Rsk1
K112/464R) was kindly provided by Dr. John Blenis, Harvard Med-
ical School. Dominant negative Rsk1 may inhibit the kinase activity
of other Rsk isoforms. However, Rsk1 is predominantly expressed
in kidney [19].
2.2. Cell culture and transfection
Rat kidney glomerular mesangial cells were grown as described
previously [4,7,10]. Mesangial cells were transfected with vector or
indicated expression plasmids using Fugene as describedFig. 1. TGFb decreases phosphorylation of eEF2 by increasing phosphorylation of eEF2K
2 ng/ml TGFb for the indicated periods of time were immunoblotted with the indicated a
incubation with TGFb for 15 min. The cell lysates were immunoblotted with the indicate[10,20,21]. Using this reagent, we routinely observe 60–80% trans-
fection efﬁciency in mesangial cells [10].
2.3. Immunoblotting
Mesangial cells were lysed in RIPA buffer (20 mM Tris–HCl, pH
7.5, 150 mM NaCl, 5 mM EDTA, 1 mM Na3VO4, 1 mM PMSF, 0.1%
protease inhibitor cocktail and 1% NP-40) and the cell debri were
separated by centrifugation to yield supernatant, which was used
to determine protein concentration as described [4,7,10,20]. Equal
amounts of proteins were separated by SDS–polyacrylamide gel
electrophoresis followed by transfer of the separated proteins to
PVDF membrane for immunoblotting with indicated antibodies
as described [4,7,10,20].
2.4. Protein synthesis assay and measurement of mesangial cell
hypertrophy
Protein synthesis was determined using 35S-methionine incor-
poration as described [7,10,21]. The cellular hypertrophy is deﬁned
by increase in protein synthesis without minimal changes in DNA
synthesis, i.e., in the absence of cell proliferation. Therefore, hyper-
trophy of mesangial cells was measured as the ratio of total protein
to number of cells as described [7,10,21].
3. Results
3.1. TGFb activates eEF2 in Erk1/2-sensitive manner
The phosphorylation of eEF2 at Thr-56 inactivates its function
to induce elongation phase of mRNA translation [11,12]. To study
eEF2 phosphorylation in response to TGFb, we immunoblotted ly-
sates of TGFb-incubated mesangial cells with phospho-eEF2 anti-
body. TGFb decreased eEF2 phosphorylation in a time-dependent
manner (Fig. 1A and Supplemental Fig. S1A). The eEF2 phosphory-
lation at Thr-56 is mediated by the highly speciﬁc eEF2K; activity
of eEF2K is impaired by phosphorylation at Ser-366 [11]. Incuba-
tion of mesangial cells with TGFb signiﬁcantly increased phosphor-
ylation of eEF2K (Fig. 1B and Supplemental Fig. S1B). Note that,
dephosphorylation of eEF2 followed the same kinetics as that of
eEF2K phosphorylation and hence inactivation (Fig. 1A and B).
TGFb is known to activate the non-Smad signaling, including
Erk1/2 [1]. TGFb increased phosphorylation of Erk1/2 in mesangial
cells (Supplementary Fig. S2). We examined the involvement ofin Erk1/2-dependent manner. (A and B) Lysates of mesangial cells incubated with
ntibodies. (C and D) Mesangial cells were treated with 5 lM U0126 for 1 h prior to
d antibodies. The quantiﬁcation of these data is provided in Supplementary Fig. S1.
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inhibitor U0126. U0126 signiﬁcantly blocked the inhibition of
phosphorylation of eEF2 in response to TGFb (Fig. 1C and Supple-
mental Fig. S1C). Furthermore, MEK inhibitor prevented TGFb-
stimulated phosphorylation of eEF2K (Fig. 1D and Supplemental
Fig. S1D). To conﬁrm the role of Erk, we used dominant negative
Erk2. Expression of dominant negative Erk2 prevented the inhibi-
tion of phosphorylation of eEF2 (Supplemental Fig. S3A). Addition-
ally, kinase dead Erk2 attenuated the phosphorylation of eEF2K
(Supplemental Fig. S3B). These results indicate that following TGFb
stimulation, Erk signal transduction pathway regulates the eEF2
dephosphorylation/activation via phosphorylation/inactivation of
eEF2K.
3.2. TGFb increases phosphorylation of p90Rsk
The Thr-366 of eEF2K represents a consensus phosphorylation
site, which is recognized by many basophilic kinases such as
p90Rsk [19]. Furthermore, p90Rsk is phosphorylated and activated
downstream of Erk1/2 by activated receptor tyrosine kinases [19].
Activated p90Rsk undergoes autophosphorylation at Ser-380 [19].
Therefore, phosphorylation of p90Rsk at Ser-380 serves as surro-
gate for activation of this enzyme. Activation of serine/threonineFig. 2. TGFb stimulates p90Rsk in Erk1/2-dependent manner. (A) Lysates of mesan
immunoblotted with the indicated antibodies. (B) Mesangial cells were treated with U01
indicated antibodies. (C) Mesangial cells were transfected with vector or dominant nega
Cell lysates were immunoblotted with the indicated antibodies. The quantiﬁcation of th
Fig. 3. Expression of kinase inactive p90Rsk prevents TGFb-induced inhibition of eEF2 p
were transfected with vector or dominant negative p90Rsk expression plasmid. For
immunoblotted with the indicated antibodies. The quantiﬁcation of these data is providkinase receptor by TGFb in mesangial cells increased phosphoryla-
tion of p90Rsk at Ser-380 in a time-dependent manner (Fig. 2A and
Supplemental Fig. S4A). U0126, which inhibits activation of Erk1/2,
signiﬁcantly attenuated the TGFb-stimulated phosphorylation of
p90Rsk (Fig. 2B and Supplemental Fig. S4B). Furthermore, expres-
sion of dominant negative Erk2 signiﬁcantly inhibited p90Rsk
phosphorylation (Fig. 2C and Supplemental Fig. S4C). These results
demonstrate that TGFb activates p90Rsk in Erk1/2-dependent
manner.
3.3. TGFb-stimulated p90Rsk regulates phosphorylation of eEF2K
Involvement of p90Rsk in TGFb-induced phosphorylation of
eEF2 was ﬁrst examined using a dominant negative p90Rsk kinase
in mesangial cells (Supplementary Fig. S5). Expression of dominant
negative p90Rsk signiﬁcantly prevented TGFb-induced inhibition
of eEF2 phosphorylation (Fig. 3A and Supplemental Fig. S6A). Fur-
thermore, inactive p90Rsk signiﬁcantly inhibited the phosphoryla-
tion of eEF2K in response to TGFb. (Fig. 3B and Supplemental
Fig. S6B). These results indicate that inhibition of the TGFb-stimu-
lated inactivating phosphorylation of eEF2K in the presence of
dominant negative p90Rsk results in reversal of TGFb-induced
reduction of phosphorylation of eEF2.gial cells incubated with 2 ng/ml TGFb for the indicated periods of time were
26 and TGFb as described in Fig. 1C. The cell lysates were immunoblotted with the
tive Erk2 plasmid. Forty-eight hours post-transfection TGFb was added for 15 min.
ese data is provided in Supplementary Fig. S4.
hosphorylation and induction of eEF2K phosphorylation. (A and B) Mesangial cells
ty-eight hours post-transfection, TGFb was added for 15 min. Cell lysates were
ed in Supplementary Fig. S6.
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cell hypertrophy
On the basis of our results above, we hypothesized that the
p90Rsk governs the elongation phase of mRNA translation by inac-
tivation of eEF2K to induce reduced phosphorylation and activa-
tion of eEF2, which results in protein synthesis. We examined
the role of p90Rsk on TGFb-induced protein synthesis in mesangial
cells. TGFb markedly increased protein synthesis (Fig. 4A). Expres-
sion of dominant negative p90Rsk signiﬁcantly inhibited TGFb-in-
duced protein synthesis (Fig. 4A). Increase in protein synthesis byFig. 4. Expression of dominant negative p90Rsk blocks TGFb-induced protein
synthesis and hypertrophy of mesangial cells. Mesangial cells were transfected with
vector or dominant negative p90Rsk followed by incubation with TGFb for 24 h. (A)
Protein synthesis was determined as 35S-methionine incorporation as described in
the materials and methods [7]. Mean ± S.E. of triplicate measurements is shown.
*P < 0.05 vs control; **P < 0.05 vs TGFb-treated by ANOVA. (B) Cellular hypertrophy
was determined by measurement of total protein per cell as described in the
materials and methods [7]. Mean ± S.E. of six measurements is shown. *P < 0.01 vs
control; **P < 0.01 vs TGFb-treated by ANOVA.TGFb causes hypertrophy of mesangial cells [7,10]. As expected,
TGFb induced signiﬁcant hypertrophy in mesangial cells (Fig. 4B).
Expression of dominant negative p90Rsk signiﬁcantly inhibited
TGFb-stimulated hypertrophy (Fig. 4B). These results indicate a
critical role of p90Rsk in TGFb-induced mesangial cell protein syn-
thesis and hypertrophy.4. Discussion
The present study explored a non-Smad signaling pathway in-
duced by TGFb to elucidate the contribution of the elongation
phase of mRNA translation to mesangial cell hypertrophy. We have
delineated a molecular pathway by which TGFb-stimulated Erk1/2
reduced the phosphorylation of eEF2 due to inactivating phosphor-
ylation of eEF2K. We identiﬁed p90Rsk as the kinase downstream
of Erk1/2 that deactivates eEF2K to cause reduced phosphorylation
and activation of eEF2 in response to TGFb. Finally, we provide evi-
dence that TGFb-stimulated p90Rsk activity contributes to protein
synthesis, resulting in mesangial cell hypertrophy.
In renal cells the proﬁbrotic action of TGFb precedes hypertro-
phy. For example, in diabetic nephropathy, the matrix amassing ef-
fect of hyperglycemia is partly mediated by TGFb. However,
glomerular, especially mesangial cell hypertrophy is followed by
matrix protein expansion. Renal cells isolated from TGFb null mice
displayed reduced hypertrophy in response to high glucose [22].
Moreover, type 1 diabetes induced in TGFb receptor II heterozy-
gous mice exhibited reduced glomerular, speciﬁcally, mesangial
cell hypertrophy [23]. We have recently reported a signiﬁcant role
of mTOR, especially of TORC1 in the induction of mesangial cell
hypertrophy in response to TGFb [10]. This action of TORC1 was
mediated by inactivation of 4EBP-1, which represses the initiation
of cap-dependent mRNA translation [9]. However, irrespective of
the mode of initiation, elongation phase of mRNA translation sig-
niﬁcantly contributes to protein synthesis to induce cellular
hypertrophy.
Dephosphorylation of eEF2 induces binding to and facilitates
translocation of mRNA on the ribosome to cause elongation of
mRNA translation [11]. Insulin in Chinese hamster ovary cells
and in primary adipocytes and myocytes decreases eEF2 phosphor-
ylation in a rapamycin-sensitive manner, indicating a role of
TORC1 in controlling the activity of eEF2K [11]. Indeed TORC1 tar-
get, S6 kinase 1, phosphorylated and deactivated eEF2K in response
to insulin [24]. In contrast to these results, we reveal that dephos-
phorylation of eEF2 in response to TGFb is sensitive to Erk1/2 inhi-
bition (Fig. 1 and Supplementary Fig. S3A). In fact Erk1/2 governed
eEF2 dephosphorylation by inducing inactivating phosphorylation
of eEF2K (Fig. 1 and Supplementary Fig. S3B).
p90Rsk consists of a family of four kinases (Rsk1-4), which
share a high degree of sequence homology. Rsk1 is predominantly
expressed in lung, pancreas and kidney, while Rsk2-4 are signiﬁ-
cantly expressed in the different areas in brain [19]. p90Rsk con-
tains two functionally distinct kinase domains joined by a linker
region with short N- and C-terminal tails. C-terminal kinase do-
main (CTKD) is homologous to the calcium-calmodulin-dependent
protein kinase and causes autophosphorylation. The N-terminal ki-
nase domain (NTKD), homologous to AGC kinase family members,
is responsible for substrate phosphorylation. p90Rsk is activated in
a highly coordinated manner, which is initiated by the activated
Erk1/2 binding to the C-terminal tail. Phosphorylation of Ser-221
in the NTKD by the PDK1 is required for activation of p90Rsk and
phosphorylation of substrates by NTKD. PDK1 is known to be acti-
vated downstream of PI 3 kinase via phosphorylation of Ser-241 it
its activation loop. In mesangial cells, we have previously shown
activation of PI 3 kinase by TGFb, [4]. Now we show that TGFb
time-dependently increases the phosphorylation of PDK1 (Supple-
4272 F. Das et al. / FEBS Letters 584 (2010) 4268–4272mentary Fig. S7). These results indicate that TGFbmay utilize PDK1
leading to activation of p90Rsk [19]. In addition, the hydrophobic
motif autophosphorylation at Ser-380 by the CTKD is necessary
for the activity of p90Rsk. In the present study, we demonstrate
that TGFb increases phosphorylation of p90Rsk at Ser-380
(Fig. 2), indicating its activation. Moreover, we provide the ﬁrst evi-
dence that, in contrast to TORC1 recruitment by insulin [16,24],
TGFb-induced non-Smad signaling uses activated p90Rsk to in-
crease phosphorylation of eEF2K (Fig. 3). Our results conclusively
demonstrate that p90Rsk contributes to dephosphorylation of
eEF2 (Fig. 3). These data are also in agreement with the observa-
tions obtained with the G-protein coupled receptors [11]. There-
fore, we conclude that TGFb receptor serine/threonine kinase
utilizes non-Smad p90Rsk signaling to induce elongation phase
of mRNA translation.
At the molecular level, increase in protein synthesis is required
for cellular hypertrophy [7,10,25]. Role of TORC1 has been exten-
sively studied in relation to mRNA translation initiation and elon-
gation phases during the progression of diabetic kidney disease
[25,26]. For example, we have recently reported that administra-
tion of rapamycin to mice with type 2 diabetes signiﬁcantly ame-
liorated the renal hypertrophy [24]. Recently, p90Rsk has been
shown to feed into the TORC1 signal transduction. Thus phorbol-
stimulated p90Rsk phosphorylates the TSC2 protein at Ser-1798,
resulting in its inactivation, leading to activation of TORC1, which
regulates both initiation and elongation processes of mRNA trans-
lation [11,25–27]. Here we present results to show direct involve-
ment of p90Rsk in TGFb-induced phosphorylation of the eEF2,
which regulates the elongation of mRNA translation. We demon-
strate that p90Rsk contributes to TGFb-stimulated protein synthe-
sis, which results in mesangial cell hypertrophy (Fig. 4). These data
demonstrate that intercepting p90Rsk may provide an attractive
new therapy to prevent mesangial hypertrophy during the early
progression of diabetic nephropathy where TGFb acts as the path-
ological cytokine.
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